Gapping up
In reaction to strong earnings/guidance:
- APHA +21.6%, SOL +6.2%, JPM +2.1%, UNH +1.9%, JNJ +1.9%, WIT +1.1%, BLK +0.8%
Other news:
- RETA +43.6% (announces that the registrational Part 2 portion of the MOXIe Phase 2 trial of omaveloxolone in patients with Friedreich's ataxia met its primary endpoint), GLUU +9.3% (to join S&P SmallCap 600)
- AMBA +5.5% (comments on Entity List Rule, does not see significant impact on current financial results and confirms guidance)
- CGC +2.7% (sold its 42,087,639 shares in Australian cannabis company AusCann via an off market block trade at $0.15 per share for gross proceeds of $6.3 million)
- STT +1% (ahead of earnings Oct 18 before the open)
- ABT +0.9% (authorizes repurchase of up to $3 bln of Abbott common shares)
- WFC +0.9% (in sympathy with JPM and ahead of earnings this morning)
Analyst comments:
- BBBY +3.3% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- OLLI +2.1% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- LOW +1.9% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- EHTH +1.8% (initiated with Outperform at Raymond James; tgt $90)
- NVDA +1.8% (target raised to $250 at BofA/Merrill)
- SFIX +1.7% (initiated with a Outperform at Robert W. Baird; tgt $28)
- SQ +0.8% (initiated with a Buy at UBS; tgt $81)
- PD +0.8% (initiated with Outperform at Robert W. Baird; tgt $31)